323P - The role of SUVmax in 18F-FDG PET/CT for assessing radiation therapy response for cervical cancer

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cervical Cancer
Staging Procedures (clinical staging)
Surgical Oncology
Presenter Seok Ho Lee
Citation Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585
Authors S.H. Lee1, K.C. Lee1, K. Sung1, E.Y. Choi1, J.B. Bae1, S.G. Kim2, H. Lee2
  • 1Radiation Oncology, Gachon University Gil Hospital, 21565 - Incheon/KR
  • 2Nuclear Medicine, Gachon University Gil Hospital, 21565 - Incheon/KR



We assessed the relationship between primary tumor 18F-fluorodeoxyglucose (FDG) uptake expressed as the maximum standardized uptake value (SUVmax), primary tumor response, and survival in patients with cervical cancer on pretreatment and posttreatment positron emission tomography-computed tomography (PET-CT).


We conducted a retrospective review of 35 cervical cancer patients (stage I-II: n = 19; stage III-IV: n = 16) treated with radiation therapy with or without chemotherapy. All patients (median age, 58.5 years; range, 37∼81 years) had FDG PET-CT scans performed before and after radiation therapy (pre- and post-RT). The SUVmax were recorded from PET-CT scans performed pre- and post-RT. The correlation between SUVmax and treatment response was evaluated and analyzed. Measurement of primary tumor volumes (pTV) for the treatment response evaluation was performed by the diagnostic radiologist using magnetic resonance imaging or abdominopelvic CT.


The median duration of follow-up was 42 months (range 5-72 months). The median SUVmax of cervical cancer pre- and post-RT were 10.1 (range: 4.31∼28.5) and 2.51 (range: 1.65∼5.91), respectively. After treatment for cervical cancer, the reduction of SUVmax (median 7.4 (range: 0.05∼25.85)) was significant (p 


The SUVmax was significantly reduced after RT for cervical cancer. This study showed that the SUVmax after RT in patients with cervical cancer was significantly correlated with the primary tumor response.

Clinical trial indentification

Legal entity responsible for the study

Gachon University Gil Medical Center


Gachon University Gil Medical Center


All authors have declared no conflicts of interest.